GlaxoSmithKline plc (GSK) today announced results from the 'LABA' (long acting beta 2-agonist) safety study, AUSTRI(SAS115359). The study compared Advair ® Diskus ®, a combination of the LABA, ...
GlaxoSmithKline is shifting its sales strategy for therapy Advair to stress increasing a treatment for chronic obstructive pulmonary disease (COPD), a new report states.Advair, a long-acting beta2 ...
Amid a Street-beating fourth-quarter report, GlaxoSmithKline quantified the hit that it’s been bracing for: Advair generics. If copycats launch midyear, as their makers hope, Glaxo figures its lead ...
Corticosteroid + long-acting beta-2 agonist (LABA). Allow approx. 12hrs between doses. Asthma: ≥12yrs: initially 1 inh of 100/50 or 250/50 or 500/50 twice daily, based on disease severity and previous ...
FDA Panel Says GlaxoSmithKline's Advair Doesn't Boost COPD Survival RESEARCH TRIANGLE PARK, N.C., May 1 -- An Advisory Committee to the U.S. Food and Drug Administration (FDA) today unanimously agreed ...
More and more branded drugs seem to be facing generic competition. The impact might not be so positive for Big Pharma giants, but this can be a serious victory for consumers and patients who are in ...
DUBLIN--(BUSINESS WIRE)--The "Drug Overview: Advair" report has been added to ResearchAndMarkets.com's offering. Advair ([fluticasone propionate + salmeterol]; GlaxoSmithKline) is a fixed-dose ...
GSK's blockbuster asthma drug, Advair, again sees a major generic competitor fail to get US regulatory approval. Hot on the heels of MYL's failure, HKMPY & VEGPF's generic also got a "major" ...
LONDON (Reuters) - A deadline for U.S. regulators to give a verdict on a generic copy of GlaxoSmithKline's (GSK.L) blockbuster inhaled lung drug Advair has passed with no sign of approval, sparking ...
LONDON, April 3 (Reuters) - GlaxoSmithKline Plc has taken a step forward in developing a successor to its top-seller Advair, as rivals snap at its dominant position in respiratory medicine. Industry ...
Advair 250/50 Now the Only Treatment Approved to Both Reduce Exacerbations and Improve Lung Function RESEARCH TRIANGLE PARK, N.C., May 1 -- Late yesterday the U.S. Food and Drug Administration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results